Petros Pharmaceuticals, Inc.
PTPICIK 0001815903 · Pharmaceutical Preparations · OTC
Revenue (TTM)
$6.06M
−12.2% YoY
Q1 May 2026
Net Income (TTM)
$1.26M
+113.4% YoY
Q1 May 2026
EPS Diluted (TTM)
−$10.72
+98.1% YoY
Q1 May 2026
Gross Margin
77.6%
Q1 May 2026
Operating Margin
-87.1%
Q1 May 2026
Net Margin
20.8%
Q1 May 2026
Free Cash Flow (TTM)
−$4.35M
Q1 May 2026
Cash
$4.35M
Q1 May 2026
Total Debt
$1.74M
Q1 May 2026
Shares Outstanding
42.37M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
Balance Sheet
Cash vs Debt
Latest news
All news →-
Low Neutral
Petros Pharmaceuticals (PTPI) Separates from Executive Mitchell Arnold
The pharmaceutical company agreed to a severance package with a departing officer, effective June 18, 2026.